Assembly Biosciences
Nicole White Ph.D. joined Assembly in 2020 and previously served as the Company’s Senior Vice President, Pharmaceutical Development and Manufacturing. Prior to joining Assembly, she headed up Process Chemistry at Gossamer Bio and led CMC for multiple early and late stage programs in development. Prior to that she held progressive leadership roles at Gilead Sciences to advance multiple programs from Phase 1 through commercial launch and helped guide the drug substance manufacturing and global outsourcing strategy. While at Gilead she contributed to the development and commercial launch of multiple antiviral programs including Harvoni®, Vemlidy® and Vosevi®. Nicole earned a Ph.D. in Organic Chemistry from the University of California, Irvine and a Bachelor of Science degree from the University of California, San Diego.
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.